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Background: Surveillance designed to detect changes in the type-specific distribution of HPV in cervical
intraepithelial neoplasia grade 3 (CIN-3) is necessary to evaluate the effectiveness of the Australian vaccination
programme on cancer causing HPV types. This paper develops a protocol that eliminates the need to calculate
required sample size; sample size is difficult to calculate in advance because HPV’s true type-specific prevalence is
imperfectly known.
Method: A truncated sequential sampling plan that collects a variable sample size was designed to detect changes
in the type-specific distribution of HPV in CIN-3. Computer simulation to evaluate the accuracy of the plan at
classifying the prevalence of an HPV type as low (< 5%), moderate (5-15%), or high (> 15%) and the average
sample size collected was conducted and used to assess its appropriateness as a surveillance tool.
Results: The plan classified the proportion of CIN-3 lesions positive for an HPV type very accurately, with >90% of
simulations correctly classifying a simulated data-set with known prevalence. Misclassifying an HPV type of high
prevalence as being of low prevalence, arguably the most serious kind of potential error, occurred< 0.05 times per
100 simulations. A much lower sample size (21–22 versus 40–48) was required to classify samples of high rather
than low or moderate prevalence.
Conclusions: Truncated sequential sampling enables the proportion of CIN-3 due to an HPV type to be accurately
classified using small sample sizes. Truncated sequential sampling should be used for type-specific HPV surveillance
in the vaccination era.Background
Infection with human Papillomavirus (HPV) is recognised
as the main cause worldwide of both cervical cancer [1-3]
and its precursor lesions, cervical intraepithelial neoplasia
grades 2 and 3 (CIN-2, 3) [4]. In 2007, following the devel-
opment of highly efficacious vaccines against oncogenic
HPV subtypes 16 and 18 [1,5,6], Australia became the first
country in the world to embark on a national vaccination
program [7,8], and other countries have now begun vari-
ous forms of program.
Ultimately, the success of such programs will be mea-
sured by the extent to which they reduce cancer incidence,* Correspondence: ewaters@kirby.unsw.edu.au
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reproduction in any medium, provided the orbut shorter term changes in benign and pre-cancerous
lesions caused by HPV can be used to assess their impact
[7]. In Australia, reductions have been reported in the inci-
dence of CIN-3, [9] and genital warts [10]. Warts are
caused by HPV types 6 and 11, which the quadrivalent
vaccine protects against in addition to HPV 16 and 18 [1].
Key indicators in the early evaluation of an HPV
vaccination program are provided by monitoring the
distribution of HPV types. It is important both to
track the expected decline in prevalence of the types
that the vaccine protects against, and to monitor the
prevalence of oncogenic types that are not the target
of current vaccines [8]. However, planning surveys of
HPV type distribution is challenging because current
prevalences are only known imprecisely, so sample
size estimates cannot be made with any confidence.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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requirements. In order to address this problem, we
developed a sequential approach to survey design,
with particular application to the monitoring of HPV
type distribution in CIN-3.Methods
Sampling strategy
The sequential sampling approach to monitoring the
prevalence of particular characteristics in a population
has been used extensively in agriculture and industry, as
well as in public health, where lot quality assurance sam-
pling methods are particularly important [11-18]. We
developed an approach based on the truncated sequen-
tial sampling method used for monitoring drug resist-
ance in HIV infection [17]. Truncated sequential
sampling differs from the Wald sampling method used
in agriculture and industry by stopping (truncating) sam-
pling when a classification of moderate prevalence can
be made; normally, sequential sampling only allows clas-
sifications of high and/ or low prevalence [12,15,17].
The underlying strategy is to start with a limited number
of specimens (Nmin), make an initial estimate of preva-
lence of the characteristic of interest (in this case, the
proportion positive for a specific HPV type), and then
continue to obtain specimens and recalculate the preva-
lence estimate until predetermined statistical criteria
have been met.
The specific criteria are that the estimate can be classi-
fied as coming from a population with a low, moderate
or high prevalence of an HPV type with an acceptably
low probability of being a false positive or a false nega-
tive [15]. Real world data are used to define thresholds
used to classify prevalence as low, moderate or high
[17]. Stopping rules, based on these thresholds and the
probability of a false positive or false negative are used
to determine whether a classification of high or low
prevalence can be made (sampling should stop) with an
acceptable probability of error or whether sampling
should continue. If a predefined maximum sample size
is collected and a classification of high or low prevalence
has not been made, prevalence is classified as moderate.
(Nmax) Stopping rules are commonly represented visu-
ally as pairs of lines on a graph delineating an area
which, if breached, mean that sampling should be
stopped and a classification made (see Figure 1) [15].
The y intercepts for the upper and lower stop lines in
Figure 1, cupper and clower, and the common slope (m)
were calculated using Wald’s formulae [17,18,20]:






















In equations [1-3] α and β are the nominal probabil-
ities of a false positive and false negative, p1 and p2 are
thresholds defining low and high prevalence and q1 and
q2 are equal to 1 - p1 and 1 - p2 [17]. The maximum
sample size, Nmax, used for truncation is determined ar-
bitrarily [17].
Applying the strategy to CIN-3
The sequential sampling approach can be used in any
population, but in the context of evaluating the impact
of HPV vaccination, it is most relevant for CIN-3. Moni-
toring HPV prevalence in normal cervical specimens, or
lower grade CIN, is known to detect a high proportion
of infections that are transient or lesions that will regress
[19], and are therefore unlikely to cause cancer, while
the time to develop invasive cancer is too long to detect
changes due to vaccination.
We used thresholds of (a) less than 5% for an HPV
type, designating low prevalence; ( b) 5-15% positive,
designating moderate prevalence; and ( c) greater than
15% positive, designating high prevalence. In Australia
only HPV 16 may occur in more than 15% of CIN-2 and
3; other types are evenly divided between those asso-
ciated with ≤5% (HPV 52, 39, 68, 66 and 82) and 5 -15%
(HPV 18, 33, 31, 58 and 73) prevalence in CIN-2 and 3
specimens [3]. We employed nominal false positive (α)
and false negative (β) probabilities of 0.01 and 0.025,
exceeding commonly used standards of α= 0.05 (statis-
tical significance) and 1-β= 0.8 (statistical power).
Based on prior experience in other fields, a starting
sample size (Nmin) of 20 specimens was considered large
enough to make a classification in many cases. The
choice of starting sample size does not affect the even-
tual classification of prevalences [17]. We used a max-
imum sample size for truncation of three times the
minimum sample size (Nmax= 60). Myatt and Bennett
[17] trialled maximum sample sizes of 25–60 when test-
ing the truncated sampling method, and found that a
sample size of 47 was adequate for a plan using similar
thresholds, so a maximum sample size of 60 was
expected to provide an appropriate balance between ac-
curacy and sampling intensity.
Assessment of the sampling plan for CIN-3
We used simulation to assess how well the sequential
sampling approach worked in classifying HPV types as
follows. First, we generated synthetic data representing
Figure 1 Graphical representation of the truncated sequential sampling plan. Classifications of high and low prevalence are based on
breaching the upper or lower stop lines after the starting sample size (Nmin) has been collected. Sampling continues when the proportion of the
sample positive for an HPV type falls between the lines. A classification of moderate prevalence is made and sampling is stopped (truncated)
when the maximum sample size (Nmax) has been collected.
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positive for an HPV type). We generated 1,000 data sets
under two different scenarios: one in which all preva-
lences between 0.00 and 1.00 were equally likely (uni-
form distribution); and another in which the most likely
prevalence (mode) was 0.05, or 5%, with a linear decay
to 0.00 at the lower limit and 1.00 at the upper limit (tri-
angular distribution). The use of an upper limit of 1.00
is legitimate because very large proportions of some
samples may be positive for high prevalence types –
HPV 16 in particular has been detected in up to 95% of
specimens in some studies [2]. The use of a triangular
distribution is intended to simulate the most frequent
sampled value for the prevalence of an HPV type being
low (0.05). At present most types other than HPV 16
and 18 occur in 0-10% of samples so this distribution
might capture the most likely value for positivity to most
types [2,3]. We then used the sampling plan to simulate
the process of sequential sampling 10,000 times from
each of the data sets. Each one of these 10,000 imple-
mentations of the sampling plan is referred to individu-
ally as a resembling iteration. The code for simulating
the implementation of the sampling plan was originally
written in R (www.r-project.org) but for this paper the
code was translated into plain C for improved efficiency.
For each of the 1,000 data sets, we summarised the re-
sult of the 10,000 resampling iterations by first calculat-
ing the proportion of times the prevalence was classified
as low, medium or high (designated PClow, PCmod and
PChigh) and the sample size required to make eachclassification. PClow, PCmod and PChigh were then plotted
against the true prevalence in each data set, to show the
relationship between the probability of classifying a
data-set as being either of low, moderate or high positiv-
ity and the true proportion positive in the data set. Vari-
ation in the sample size collected was summarised using
tables. Graphs were created using SigmaPlot 8.0 (Systat,
Richmond, CA, USA).
The rate at which incorrect classifications were made
over all sampling iterations was also calculated. Incorrect
classifications were sub-categorised as incorrect classifi-
cations of low, moderate or high prevalence. Gross mis-
classifications are those in which a sample with truly
high prevalence is classified as having low prevalence, or
vice versa [17]. The rate at which each of these types of
gross misclassification occurred was also recorded and
the results tabulated.
Results and discussion
The sequential sampling strategy resulted in correct
classification of HPV prevalence in> 90% of resampling
iterations (see Table 1). Figure 2 shows that over 10,000
resampling iterations on a data-set in which the propor-
tion positive for HPV type was 0.001 (i.e. clearly low
prevalence) or 0.55 (clearly high prevalence), the sam-
pling strategy always led to a correct classification. In a
more difficult case, for example where the positive pro-
portion was very close to the high prevalence threshold
(0.149), the sequential strategy still performed very well,
returning a classification of moderate prevalence on
Table 1 Rate and type of incorrect classifications during all sampling iterations
Distribution of HPV
positivity













Low 1.24 High Low 1.31*10-2
Uniform Moderate 1.23 Low High 1.49*10-2
High 3.91
Low 2.21 High Low 1.92*10-2
Mode= 0.05 Moderate 2.04 Low High 3.47*10-2
High 6.1
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low prevalence almost never. The results shown in Figure 2
differed little whether the plan was employed on data-sets
across which HPV positivity was distributed uniformly or
where positivity was most frequently around 5% (triangular
distribution). Therefore, for clarity of interpretation of Fig-
ure 2, only curves and scatter from the uniform distribution
scenario are presented.
The most serious kind of gross misclassification is argu-
ably when a plan classified a sample as having a “low”
prevalence when it was in fact “high”. This type of error oc-
curred very rarely (less than 0.05 times per 100 resampling
iterations – see Table 1). Serious classification errors oc-
curred more often under the scenario where prevalences
were clustered around 0.05 (triangular distribution) than
under the uniform scenario because a higher proportion ofFigure 2 Probability of classifying prevalence as low, moderate, or hi
true prevalence (the x axis) sampled from a uniform distribution. The
high prevalence.data sets had HPV positivity between 0 - 20% because of
the peaked nature of the sampling distribution (35%
vs.18%). These types of errors were still extremely rare
however, also occurring less than 0.05 times per 100 resam-
pling iterations (see Table 1).
A much higher sample size was required to classify sam-
ples with low prevalence than high prevalence (see Table 2).
This is not unexpected given the negative intercept of the
lower stop line (see Figure 1), which mandates that if preva-
lence is low a substantial number of samples are required
to determine this. The sample size required to make a clas-
sification of moderate prevalence could obviously be
reduced by arbitrarily lowering the value of Nmax, but little
would be gained by doing so as it would result in more op-
portunities of misclassifying samples of low prevalence as
having moderate prevalence (inspect Figure 1). Thesegh over 10,000 resampling iterations over1,000 data sets with
dashed vertical lines represent the classification thresholds for low and
Table 2 Mean sample size collected over 10,000
resampling bouts from 1,000 simulated data sets with
uniformly distributed HPV positivity, and over 10,000
resampling bouts from 1,000 data sets with a triangular





Sample size collected to classify
proportion positive for HPV type
Mean St. dev.
Low 40.76 5.73
Uniform Moderate 48.27 4.51
High 21.29 3.46
Low 43.37 4.83
Mode= 0.05 Moderate 48.91 4.22
High 22.51 4.54
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employed by using it only to monitor HPV types that are
more common.
In practical applications of this method, pathology ser-
vices could prepare specimens from cervical samples
and send them to a suitable reference laboratory [7].
After analysis at the reference laboratory, proportions
positive for given HPV types would be recorded; on
reaching the starting sample size, the number positive
for an HPV type would be compared to the stop chart in
Figure 1, and a determination made about whether more
specimens were required. Though a strict application of
sequential sampling would require a single additional
specimen be analysed if required, it would be more prac-
tical to increment by five. This would not fundamentally
undermine the sequential sampling approach, but it
could reduce its efficiency by resulting in more samples
being analysed than required.
The use of the resampling method for validation has
some affinities with how the plan might be used in real-
ity, as the plan might well be employed multiple times
on one sample to classify positivity of multiple HPV
types without a loss of precision, providing the risk of
infection with one HPV type is not affected by infection
with another, as appears to be the case [20,21]. It should
be noted that random sampling is not assumed or
required in sequential sampling [14,15].
Conclusion
Truncated sequential sampling represents a practical
scheme for conducting type-specific surveillance of HPV
in pre-cancerous lesions. It eliminates the need to accur-
ately calculate a priori sample size and makes no
assumptions about current HPV type distribution. Dur-
ing resampling, it classified prevalence of an HPV type
with> 90% accuracy. This is not unexpected as the plans
utilised a far higher statistical power (nominal type II
errors of 2.5%) than implied by the 20% type II error rateoften used as a benchmark in sample size calculations. A
much lower average sample size (21–22 versus up to 48)
was required to accurately classify high prevalence sam-
ples. Truncated sequential sampling represents a prac-
tical, efficient method of conducting HPV type-specific
surveillance in the absence of accurate, prior informa-
tion about type specific prevalence, and is especially effi-
cient at classifying the likely prevalence of more
common HPV types.
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